Lipid-altering therapies and the progression of atherosclerotic disease. - Wikidata - wikimedia - TriplyDB

Lipid-altering therapies and the progression of atherosclerotic disease.

Lipid-altering therapies and the progression of atherosclerotic disease.

http://www.wikidata.org/entity/Q36700545

about

Intravascular ultrasound: principles and cerebrovascular applications.2,4,5-trimethoxycinnamic acid: the major metabolite of alpha-asarone, retains most of the pharmacological properties of alpha-asarone.Changes in lipid profile of patients referred to a cardiac rehabilitation program.

P2860

Q37687684-96B2AC85-A1C2-415A-AC18-B4D1323A0044 Q46441231-C2C5E833-978B-4B20-92B4-95AF01B3AEB7 Q46447895-A184B2D6-0BDC-402B-B4F4-9534BBB0B378

P2860

Lipid-altering therapies and the progression of atherosclerotic disease.

http://www.wikidata.org/entity/Q36700545

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Lipid-altering therapies and the progression of atherosclerotic disease.

@ast

Lipid-altering therapies and the progression of atherosclerotic disease.

@en

type

label

Lipid-altering therapies and the progression of atherosclerotic disease.

@ast

Lipid-altering therapies and the progression of atherosclerotic disease.

@en

prefLabel

Lipid-altering therapies and the progression of atherosclerotic disease.

@ast

Lipid-altering therapies and the progression of atherosclerotic disease.

@en

P1433

Q36700545-1E288B02-C76C-4E99-9FCE-CB4FEA7449B4

P1476

Q36700545-65C46658-068F-40FB-B1F5-74FBFD495A14

P2860

Q36700545-419C1D64-ACC8-4026-A931-A36C1316C59F

Q36700545-568774DB-1FA3-4266-BE6A-18B33C1ED20F

Q36700545-5DB2BFD5-45EC-42D6-ABD7-2487D484AEF2

Q36700545-7724911E-6991-4E92-A636-DA4555DC0C1C

Q36700545-7CFE44C8-B927-4AA1-A46C-77A9945A06F7

Q36700545-7E2C5A20-C859-4934-9025-ED1595BD2F85

Q36700545-8805868F-E361-4CD7-AEB1-B81FC4570011

Q36700545-BA3BD80F-A74A-4FD8-9EB1-09013FFFFAE4

Q36700545-CDA0B529-B8D7-4E7B-93CC-ABED5DEF6EF6

Q36700545-E8D6CB90-AD42-4731-8724-29B9E857CBA7

P2888

Q36700545-B3BFC4FA-AC2E-4C70-B485-811052967858

P304

Q36700545-9362D6CD-D89B-4913-A0CF-F606575FB290

P31

Q36700545-46882A15-8AEC-4ED5-9861-8D23BA9516FC

P356

Q36700545-77BC1E07-CD83-4733-8239-C56C7BC5265D

P433

Q36700545-F3652953-FDBB-4D26-9169-4803686A0C43

P478

Q36700545-A191099C-7D39-4093-BD69-C3C1E42EE230

P50

Q36700545-624F6480-8901-4840-9623-BE61CF3DE922

P577

Q36700545-C6A0D9E2-355A-4FDA-86AE-D7F1DD92965D

P698

Q36700545-DC2C09E1-874D-457E-BAA3-0BEE5C07F020

P921

Q36700545-8E41B585-FDD5-407F-8B90-FE533F2800DE

P356

S00270-006-0183-8

P1433

CardioVascular and Interventional Radiology

P1476

Lipid-altering therapies and the progression of atherosclerotic disease.

@en

P2860

Systematic review on the risk and benefit of different cholesterol-lowering interventions

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

Coronary plaque disruption.

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials.

Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention.

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

P2888

s00270-006-0183-8

P304

155-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00270-006-0183-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Anthony S Wierzbicki

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17206389

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis